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Abstract
Purpose Despite positive responses in phase II clinical trials, the bioreductive prodrug apaziquone failed to achieve statisti-
cally significant activity in non-muscle invasive bladder cancer in phase III trials. Apaziquone was administered shortly after 
transurethral resection and here we test the hypothesis that haematuria inactivates apaziquone.
Methods HPLC analysis was used to determine the ability of human whole blood to metabolise apaziquone ex vivo. An 
in vitro model of haematuria was developed and the response of RT112 and EJ138 cells following a 1-h exposure to apaz-
iquone was determined in the presence of urine plus or minus whole blood or lysed whole blood.
Results HPLC analysis demonstrated that apaziquone is metabolised by human whole blood with a half-life of 
78.6 ± 23.0 min. As a model for haematuria, incubation of cells in media containing up to 75% buffered (pH 7.4) urine and 
25% whole blood was not toxic to cells for a 1-h exposure period. Whole blood (5% v/v) significantly (p < 0.01) reduced 
the potency of apaziquone in this experimental model. Lysed whole blood also significantly (p < 0.05) reduced cell growth, 
although higher concentrations were required to achieve an effect (15% v/v).
Conclusions The results of this study demonstrate that haematuria can reduce the potency of apaziquone in this experimental 
model. These findings impact upon the design of further phase III clinical trials and strongly suggest that apaziquone should 
not be administered immediately after transurethral resection of non-muscle invasive bladder cancer when haematuria is 
common.
Keywords Apaziquone · Non-muscle invasive bladder cancer · Haematuria
Introduction
Apaziquone, originally known as EO9 (3-hydroxy-5-aziridi-
nyl-1- methyl-2-(1H-indole-4,7-dione)prop-β-en-α-ol), has 
had a long and chequered history culminating in its clinical 
evaluation against non-muscle invasive bladder cancer [1, 
2]. Whilst its pharmacokinetic properties are undesirable 
for systemic administration, they are paradoxically advan-
tageous in the treatment of non-muscle invasive bladder 
cancer (NMIBC) where intravesical administration ensures 
adequate delivery to the tumour site and any drug leaching 
out into the blood stream is rapidly removed leading to low 
risk of systemic side effects. Apaziquone is a bioreductive 
prodrug that requires enzymatic activation to DNA damag-
ing species [2] and following the demonstration that NMIBC 
possesses the appropriate enzymology to activate apaz-
iquone [3, 4], significant ablative activity against NMIBC 
marker lesions was reported in phase I and II clinical trials 
[5, 6]. The level of activity observed in marker lesion studies 
was higher than that reported for other chemotherapy drugs 
and immune response modifiers [7] and 2-year response 
rates demonstrated that long-term responses were good in 
comparison to other ablative studies [8, 9]. The results of 
two phase III clinical trials were, however, disappointing, 
and when analysed individually, both studies failed to reach 
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statistical significance for the primary end point which was 
the 2 year recurrence rate [10].
To try and explain the stark differences in outcomes 
between the phase III trial and marker lesion studies, we 
focus in this study on key differences in the design of these 
clinical trials. The major difference between the two sets of 
studies was that a single dose of apaziquone was adminis-
tered intravesically within 24 h of transurethral resection 
of bladder tumours (TURBT) in phase III studies, whereas 
apaziquone was administered weekly for 6 weeks starting 2 
weeks after TURBT in the marker lesion studies. There is 
therefore a difference in the timing of drug administration 
relative to TURBT and a reduction in the cumulative dose 
given to patients in the phase III study. Haematuria is com-
mon following surgical resection of tumours and, in 2002, 
we demonstrated that apaziquone is rapidly metabolised by 
murine whole blood [11]. Whilst the context of these stud-
ies focused on the design of second-generation analogues 
of apaziquone that had better pharmacokinetic properties, 
this observation has direct relevance to the clinical prob-
lem outlined above. Administration of apaziquone immedi-
ately after surgery when haematuria is common could affect 
the potency and therefore efficacy of apaziquone. Post hoc 
analysis of the data generated in the phase III trial did in 
fact reveal that a subset of patients who received apaziquone 
within 30 min of TURBT had no difference in response rate 
compared to the placebo arm [10]. In contrast, patients who 
received apaziquone between 30 and 90 min after TURBT 
demonstrated a highly significant response to apaziquone in 
terms of 2-year recurrence rates. Our hypothesis therefore is 
that haematuria immediately after surgery causes a reduction 
in the efficacy of apaziquone when administered immedi-
ately after TURBT. In this study, experimental evidence is 
provided demonstrating that apaziquone is metabolised by 
human blood and this reduces the potency of apaziquone in 
an in vitro model of haematuria. These findings have impli-
cations for the design of future phase III clinical trials and 
these are discussed within.
Materials and methods
Metabolism of apaziquone by human blood
The metabolism of apaziquone by human whole blood was 
performed as described elsewhere [11]. Following informed 
consent, blood samples were obtained from healthy volun-
teers, collected in EDTA tubes [BD vacutainer K2E (EDTA)] 
and either used as ‘whole blood’ or plasma (obtained by cen-
trifuging blood at 3000g for 5 min). Whole blood or plasma 
samples were spiked with apaziquone (20 µM) and incu-
bated at 37 °C for various times. Apaziquone was extracted 
from samples by the addition of ice-cold acetonitrile with 
a solvent/sample ratio of 2:1 and centrifuged at 7000g for 
5 min to remove precipitated proteins. Samples were ana-
lysed by reverse phase HPLC [12] using a LiChrosorb RP-18 
column and a Waters 996 Photodiode Array detector. The 
mobile phase was phosphate buffer (10 mM, pH 7.0)/metha-
nol (57/43) and the flow rate was 1.2 ml/min. Identical stud-
ies were conducted using phosphate-buffered saline (PBS at 
pH 7.4). PBS spiked with 20 µM apaziquone (t = 0) was used 
as the 100% control and recovery from biological samples 
was expressed as a percentage of the PBS control.
Cell lines and chemosensitivity studies
RT112 and EJ138 human bladder carcinoma cell lines were 
obtained from ECACC and routinely maintained as mon-
olayer cultures in RPMI1640/DMEM (50:50 mix) contain-
ing foetal calf serum (10% v/v) and l-glutamine (2 mM). 
Purified, unformulated apaziquone was obtained from Spec-
trum Pharmaceuticals Inc. and stock solutions at 100 mM 
were prepared in DMSO, aliquoted and stored at − 20 °C. 
For chemosensitivity studies performed under standard cell 
culture conditions, cells were plated into 96-well plates at 
2 × 103 cells per well and incubated overnight to adhere. The 
following day, cell culture media were removed and replaced 
with media containing a range of apaziquone concentrations 
(10–0.196 µM using a twofold serial dilution strategy). Cells 
were exposed to apaziquone for 1 h (to mimic the 1-h instil-
lation protocol used in the clinic), following which they were 
washed three times with PBS before the addition of 200 µl 
of media to each well. Cells were subsequently incubated 
at 37 °C for 96 h before growth inhibition determination 
using the MTT assay as described elsewhere [12]. Briefly, 
culture media were removed from each well and replaced 
with 200 µl of fresh media prior to the addition of 20 µl of 
MTT (5 mg/ml). Following a 4-h incubation at 37 °C, media 
were removed and formazan crystals dissolved in 150 µl of 
DMSO per well. The absorbance of the resulting solution 
was determined spectrophotometrically at 540 nm and cell 
growth was determined as the true absorbance of treated 
cells divided by the true absorbance of control cells and 
expressed as a percentage. Three independent experiments 
were performed and the results are presented as the mean 
 IC50 values ± standard deviation.
Apaziquone is known to be active against both aerobic 
and hypoxic cells [13], but all studies were conducted against 
aerobic cells for the following reasons. First, the phase III 
studies were conducted in patients that had all tumours sur-
gically removed and therefore there were no solid masses 
where hypoxia could exist. Second, the vehicle used in the 
instillation was well oxygenated (in equilibrium with atmos-
pheric conditions) and the administration of 40 ml directly 
into the bladder would be expected to create local conditions 
that would be aerobic. Based on the above considerations, 
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it would be unlikely that conditions in the bladder would be 
conducive to the hypoxia activation of apaziquone and this 
was therefore not evaluated.
Chemosensitivity studies in the presence of urine 
and whole blood
To determine the amount of blood and urine that cells in 
culture will tolerate, cells were exposed to varying amounts 
of urine or blood for 1 h and cell survival was determined 
96 h later using the MTT assay as described above. Follow-
ing informed consent, blood samples were obtained from 
healthy volunteers and placed into EDTA tubes. For studies 
using whole blood, samples were initially diluted 1:1 in cell 
culture media followed for subsequent twofold serial dilution 
in media to generate a range of blood dilutions (50–0.098% 
v/v). Cell culture plates were set up as described above and 
following a 1-h exposure to media containing whole blood 
at different concentrations, cells were washed, culture media 
added (200 µl/well) and incubated for a further 96 h before 
percentage growth inhibition was determined using the MTT 
assay as described above. In addition, as haemolysis is com-
monly observed in haematuria, similar studies were con-
ducted using lysed whole blood (obtained by repeated cycles 
of rapid freezing in liquid nitrogen and thawing at 37 °C).
Mid-flow urine samples were obtained from healthy vol-
unteers and used immediately. Urine samples were either 
applied directly to cells or pH adjusted to 7.4 using NaOH 
prior to addition to cells. Unbuffered or pH-adjusted urine 
was diluted in culture media to give a range of urine concen-
trations and these were applied to cell cultures as described 
above. Following a 1-h incubation, cells were washed and 
culture media added (200 µl/well). Following a further 96-h 
incubation at 37 °C, percentage cell growth was determined 
using the MTT assay as described above.
Results
Metabolism of apaziquone by whole blood 
and plasma
The metabolism of apaziquone in human whole blood, 
human plasma and PBS is presented in Fig. 1a. Whilst apaz-
iquone is stable in PBS and plasma over a 2-h period, levels 
of apaziquone decrease significantly in a time-dependent 
manner (Fig. 1a). No metabolites (specifically the inac-
tive products EO5A and EO9-Cl [14]) were observed on 
chromatograms (data not shown) suggesting that any active 
metabolites of apaziquone are irreversibly bound to cellular 
components of whole blood and remain within the protein 
precipitate.
Response of EJ138 and RT112 cells to apaziquone
The response of cell lines following a 1-h exposure to apaz-
iquone are presented in Fig. 1b. Both cell lines are sensi-
tive to apaziquone with  IC50 values of 1.11 ± 0.09 and 
0.915 ± 0.291 µM for RT112 and EJ138 cells, respectively. 
In both cell lines, a 1-h exposure to apaziquone at 5 µM 
induces a 95% growth inhibition, so this concentration was 
chosen for subsequent experiments to determine the effect 
of blood and urine on the activity of apaziquone.
Response of EJ138 and RT112 cells to urine 
and whole blood
The effect of whole blood and urine on the proliferation of 
cells is presented in Fig. 1c, d, respectively. The addition of 
whole blood onto cells for a period of 1 h has no effect on 
cell survival up to 25% v/v. At 50% v/v, however, substantial 
cell killing occurred along with problems with clotting in 
the wells. For subsequent experiments, therefore, the high-
est concentration of whole blood used was 25% v/v. Whilst 
difficult to establish the clinical relevance of this concentra-
tion of whole blood in these experiments, it is known that 
haematuria following TURBT is both common and can vary 
between mild to gross haematuria that requires further medi-
cal intervention [15]. Exposure of cells to unbuffered urine 
(in the experiment in Fig. 1d, the pH of the urine was 5.93) 
led to a dose-dependent reduction in cell growth. Cells were 
however able to tolerate up to 90% urine once pH had been 
adjusted to pH 7.4. For subsequent experiments, pH-adjusted 
urine (pH 7.4) at 75% (v/v) was used.
In summary, the results presented in Fig. 1b–d define the 
parameters within which subsequent experiments were per-
formed. These include (i) the concentration of apaziquone (5 
µM) that induces > 95% cell growth inhibition, (ii) an upper 
limit for the amount of whole blood that can be used (25% 
v/v) without affecting cell growth and (iii) the amount of 
buffered urine that can be used without causing significant 
inhibition of cell growth (75% v/v).
Response of EJ138 and RT112 cells to apaziquone 
in buffered urine and whole blood
The results presented in Fig. 2a, b clearly demonstrate that 
the inclusion of whole blood (5%) and buffered urine (75%) 
significantly (p < 0.01) reduces the potency of apaziquone. 
Whilst apaziquone induces a > 95% cell killing in both 
RT112 and EJ138 cells in the absence of whole blood, the 
inclusion of whole blood (5% v/v) significantly increases cell 
survival in RT112 (p = 0.0029) and EJ138 (p = 0.0004) cells. 
The effect of buffered urine on the activity of apaziquone 
is negligible, as cell growth inhibition in the positive con-
trols is similar to cell growth inhibition in media (compare 
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Fig. 2a, b with Fig. 1b). The results obtained using lysed 
whole blood are presented in Fig. 2c, d. In both cell lines, 
a small but statistically significant (p < 0.05) reduction in 
the potency of apaziquone was observed when lysed whole 
blood (at concentrations of 15% and above) was added to 
buffered urine. This effect was dose dependent with respect 
to the amount of lysed whole blood included in the assay. 
In contrast to the whole blood experiments where highly 
significant reductions in activity were observed at 5% whole 
blood, the effect of lysed whole blood on the activity of 
apaziquone was lower.
Discussion
The main reason for the change in the protocols between 
apaziquone phase III and marker lesion studies was to com-
ply with current guidance for intravesical chemotherapy 
issued by the European Association of Urology (EAU) and 
American Urological Association (AUA). A series of studies 
indicate that a single instillation of chemotherapy immedi-
ately after resection reduces the risk of recurrence [16–19] 
with the most benefit seen with mitomycin C and epirubicin. 
The EAU guidelines therefore recommend immediate intra-
vesical instillation of chemotherapy after surgical resection 
of low to intermediate risk NMIBC. The AUA guidelines 
differ slightly in that intravesical administration of chemo-
therapy (mitomycin C or epirubicin) should be considered 
within 24 h of surgical resection for low to intermediate risk 
NMIBC patients. Whilst there is strong clinical evidence for 
the immediate intravesical administration of mitomycin C 
or epirubicin after TURBT, the results of this study suggest 
that the same principles and guidance may not be applicable 
to apaziquone.
In contrast to the structurally related mitomycin C which 
is not metabolised by murine whole blood, our previous 
studies have demonstrated that apaziquone is rapidly metab-
olised by murine whole blood [11]. In this study we demon-
strate that apaziquone is also metabolised by human blood 
(Fig. 1a), albeit at a reduced rate compared to murine blood. 
Fig. 1  Metabolism of apaz-
iquone by human blood and 
establishment of the haematu-
ria model. a Time-dependent 
metabolism of apaziquone 
following incubation at 37 °C 
in whole blood (filled circle), 
plasma (unfilled circle) and PBS 
(unfilled square). Each value 
represents the mean ± standard 
deviation for three independent 
experiments. The response of 
EJ138 and RT112 cells follow-
ing a 1-h exposure to EO9 is 
presented in b. Values represent 
the mean ± standard deviation 
for three independent experi-
ments. The response of cells 
to whole blood and urine are 
presented in c and d, respec-
tively. Exposure times were 1 h 
and each result represents the 
mean ± standard deviation for 
eight replicates
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The fact that apaziquone is stable in both PBS and plasma 
suggests that chemical instability and protein binding are not 
responsible for the loss of apaziquone. Furthermore, the fact 
that no metabolites were detected using HPLC supports the 
argument that apaziquone is being metabolised to products 
that are irreversibly bound to cellular macromolecules that 
cannot be recovered using acetonitrile extraction techniques.
Apaziquone is a prodrug that requires enzymatic acti-
vation to generate cytotoxic intermediates with one and 
two electron oxidoreductases playing a prominent role in 
drug activation [2]. The identification of enzymes capable 
of metabolising apaziquone in human blood has not been 
elucidated in this study, but it is important to recognise that 
the RBC component of whole blood is not just concerned 
with the transport and release of oxygen but it has other 
metabolic functions that impact upon the pharmacokinetic 
and pharmacodynamic property of drugs including anti-
cancer agents [20, 21]. These metabolic functions extend 
to redox reactions, nitric oxide metabolism and glutathione 
metabolism [22, 23], all of which can affect the pharma-
cology of anti-cancer drugs. Furthermore, red blood cells 
are known to contain high levels of NADH cytochrome b5 
reductase (CYB5R), an enzyme that has been implicated in 
the bioreductive activation of quinone-based drugs including 
mitomycin C [24, 25]. A direct role for CYB5R in the acti-
vation of apaziquone has not however been established and 
further studies are required to fully understand the detailed 
metabolism of apaziquone by human whole blood. The 
impact of this study however resides in the development of 
an in vitro model of haematuria and the demonstration that 
the efficacy of apaziquone is reduced under experimental 
conditions that mimic haematuria. This study suggests that 
Fig. 2  Response of RT112 
and EJ138 cells to EO9 in 
the presence and absence of 
whole blood and lysed whole 
blood. a, b Response of RT112 
and EJ138, respectively, to a 
1-h exposure to apaziquone 
(5 µM) in buffered urine (75% 
v/v) without (0) or with whole 
blood (5% v/v). Following 
drug exposure, cell growth was 
determined 96 h later using the 
MTT assay. c, d RT112 and 
EJ138 treated with apaziquone 
(5 µM), urine (75%) and various 
concentrations of lysed whole 
blood. Exposure to experi-
mental conditions was for 1 h, 
followed by a 96 h recovery 
period prior to the assessment 
of cell growth using the MTT 
assay. Control experiments (c) 
used media plus apaziquone 
only (no urine or lysed whole 
blood). Statistical analysis was 
performed using a paired t test 
comparing the effects of each 
treatment with that of controls 
(** and * denote statistical 
significance at p < 0.01 and 
p < 0.05, respectively)
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the administration of apaziquone immediately after TURBT 
when haematuria is common could reduce the efficacy of 
apaziquone. Whilst the level of haematuria was not reported 
in phase III clinical trials, the presence of whole blood or 
lysed whole blood in the bladder immediately (less than 
30 min) after TURBT is a common observation and there-
fore a potential contributing factor that could explain the 
reduced efficacy of apaziquone observed in phase III clini-
cal trials.
With regard to the continued development of apaziquone, 
a further phase III clinical trial is required to address the 
post hoc analysis of the results and subsequent hypotheses 
generated during the previous phase III studies (FDA brief-
ing document). Based on the results of this study, immediate 
instillation of apaziquone should not be performed with a 
preference for instillation 60 ± 30 min after surgery when 
haematuria is reduced or non-existent. Another potential 
way of circumventing the effects of haematuria is to increase 
the dose administered. A dose escalation was performed in 
a clinical pilot study [5] and 4 mg/40 ml was selected as the 
dose that induced no systemic or local side effects. This dose 
was used for all subsequent clinical studies including the 
phase III clinical trials. A dose of 8 mg/40 ml induced some 
local toxicities (grade 2/3 dysuria and haematuria), but was 
also well tolerated.
In conclusion, the results of this study have demonstrated 
that haematuria can reduce the efficacy of apaziquone in 
experimental models in vitro and this is a potential expla-
nation for the poor efficacy of apaziquone when adminis-
tered within 30 min of TURBT. These results were used to 
inform the design of the current active phase III clinical trial 
(NCT03224182) where apaziquone is administered intra-
vesically 60 ± 30 min after TURBT at a dose of 8 mg/40 ml.
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